Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01716806 · ClinicalTrials.gov registry record · Phase 2
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
A Phase 2 study of Peripheral T-Cell Lymphoma and Hodgkin Disease, sponsored by Seagen.
- Completed
- Registry status
- Phase 2
- Development phase
- 131
- Enrollment target
- 20
- Study locations
NCT01716806: Completed Phase 2 study of Peripheral T-Cell Lymphoma and Hodgkin Disease, sponsored by Seagen.
NCT01716806 is a Phase 2 study of Peripheral T-Cell Lymphoma and Hodgkin Disease that has completed, run by Seagen. The registered enrollment target is 131 participants, above the 102-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (28% higher). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01716806, a Phase 2 study of Peripheral T-Cell Lymphoma and Hodgkin Disease, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 131 participants
- Enrollment target
- 20
- Study locations
Study Summary
This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study will look at brentuximab vedotin alone and combined with other drugs.
Primary Outcome
Objective response rate (ORR) per investigator was defined as the percentage of subjects with complete response (CR) or partial response (PR) through the end of study or prior to the start of new anti-cancer treatment (including stem cell transplant, and excluding consolidative radiotherapy) other than the study treatment. For Parts A, B, and C the response was assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson 2007).
Conditions Studied
Interventions
- DRUG nivolumab
- DRUG brentuximab vedotin
- DRUG bendamustine
- DRUG dacarbazine
Study Locations (20)
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Arizona Oncology Associates, PC - HOPE - Tucson
- Arizona Cancer Center / University of Arizona - Tucson
California
- Providence St Joseph Medical Center - Burbank
- City of Hope National Medical Center - Duarte
- Wilshire Oncology Medical Group Inc. - Pomona
Alabama
- University of Alabama at Birmingham - Birmingham
- University of South Alabama - Mitchell Cancer Institute - Mobile
Georgia
- IACT Health - Columbus
- Georgia Cancer Specialists / Northside Hospital Cancer Institute - Sandy Springs
Illinois
- Rush University Medical Center - Chicago
- Illinois Cancer Specialists / Advocate Lutheran General Hospital - Niles
Alaska
- Alaska Urological Institute - Anchorage
Arkansas
- Highlands Oncology Group - Springdale
Colorado
- Rocky Mountain Cancer Centers - Aurora - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2012-10-31 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 2 |
What the finished NCT01716806 record still lists
NCT01716806 is an interventional study that assigns participants to a tested intervention. The registered 131 participants enrollment target is mid-sized for trials with a published cap, above the 102-participant average among 34 other Peripheral T-Cell Lymphoma trials with a reported enrollment target (28% higher).
The record links to 2 conditions, with Peripheral T-Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which nivolumab is the first listed.
NCT01716806 names 20 study sites across 13 states, led by Arizona, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT01716806 about?
NCT01716806 is a clinical study titled "A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)". This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them unable to have standard chemotherapy treatment. The study ...
What is the current status of trial NCT01716806?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2012-10-31. Estimated completion is 2023-09-12.
What conditions does trial NCT01716806 study?
This clinical trial studies the following conditions: Peripheral T-Cell Lymphoma, Hodgkin Disease.
What interventions are being tested in trial NCT01716806?
The interventions under investigation include: nivolumab (DRUG), brentuximab vedotin (DRUG), bendamustine (DRUG), dacarbazine (DRUG).
Who is sponsoring clinical trial NCT01716806?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01716806 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral T-Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01716806's enrollment target sits among peer trials
131 6th of 34 higher than 28 of 34 other Peripheral T-Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peripheral T-Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
RECRUITING · Phase 2
-
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
RECRUITING · Phase 2
-
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RECRUITING · Phase 2
-
Amping up With PemJAK
RECRUITING · Phase 2
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03051464 · 131 participants · Phase 2
No Surgery Trial / Two Dose-escalation Strategies
- NCT04301843 · 131 participants · Phase 2
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
- NCT04748549 · 131 participants · NA
Intraoperative VR for Older Patients Undergoing TKA
- NCT05951179 · 131 participants · Phase 2
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI